2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide GABA_A Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases and disorders responsive to GABA_A receptor modulation lack effective compounds that can specifically target and modulate these receptors without toxic side effects.
Innovation Solution
Development of compounds of formula I or their tautomeric isoforms, which are non-toxic and pharmaceutically acceptable, that bind to GABA_A receptors, including 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamides and their salts or pro-drugs, for use in pharmaceutical compositions to treat various conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for GABA_A receptor modulation are used, then therapeutic effects are achieved, but toxic side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of GABA_A receptor modulators through systematic variation of R1 and R2 substituents on the aryl ring. This structural optimization allows tuning of pharmacological properties to achieve therapeutic efficacy while reducing toxic side effects, resolving the contradiction between reliability and harmful factors.
Solution Approach 2:
The patent employs local quality by introducing specific substituents at different positions (R1 at para position, R2 at meta position) of the aryl ring. Each position can be independently optimized with different functional groups to enhance therapeutic activity at the target site while minimizing systemic toxicity, thus addressing the contradiction between efficacy and side effects.
2Reliability
If specific GABA_A receptor modulators are developed, then therapeutic efficacy is improved, but compound complexity increases
Solution Approach 1:
The patent achieves universality by developing a core thioacrylamide structure with variable aryl substituents that can target multiple GABA_A receptor subtypes. This unified molecular framework provides broad therapeutic applicability while maintaining manageable structural complexity through systematic substitution patterns rather than entirely different molecular classes.
3Reliability
If novel compounds are synthesized with optimized structures, then therapeutic effectiveness increases, but manufacturing difficulty increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into a core thioacrylamide framework and variable aryl substituent components. This modular approach allows independent synthesis and optimization of each segment, facilitating streamlined manufacturing processes while achieving optimized therapeutic effectiveness through systematic combination of pre-synthesized building blocks.
Data Source
AI summary
A compound of the formula (I) or a tautomeric isoform thereof wherein R1 is selected from the group consisting of halogen, nitro, lower alkyl sulfonyl, cyano, trifluromethyl lower alkyl, lower alkoxy, lower alkoxycarbonyl, carboxy, lower alkyl aminosulfonyl, perfluoro lower alkyl, lower alkylthio, hydroxy lower alkyl, alkoxy lower alkyl, lower alkylthio lower alkyl, lower alkylsulfinyl lower alkyl, lower alkylsulfonyl lower alkyl, lower alkylsulfonyl, lower alkanoyl, aroyl, aryl, aryloxy and R2 is selected from the group consisting of hydrogen, alkyl, alkoxy, alkylthio, and alkylcarbonyl, and their non-toxic, pharmaceutically acceptable base addition salts or pro-drugs thereof. The compounds of the invention are useful in the treatment of nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex.